The in vivo efficacy of anti-HER2/neu TCR T cells was demonstrated in a HER2/neu-expressing xenograft model, where treated mice exhibited significant and sustained tumor growth suppression compared to both non-transduced T cells and untreated controls. This evidence concerns the gene ERBB2 and neoplasm.